This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNAediting technology development. This platform technology …
… review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also … Agency (EMA) and US Food & Drug Administration (FDA). RNAediting technology – accelerate development of the …
… Always excited about RNA therapies He is one of the founders of ProQR, but even … to choose RNA therapy over gene therapy or even gene editing using CRISPR-Cas, the latest hype. And the main … are still expanding our toolbox. We can now do single base RNAediting, turning a single A nucleotide into an I. It …
